Drug Approval | May 20, 2023
Strides Puducherry facility receives EIR from USFDA
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Testing supporting allergy diagnosis now accessible to more people in more communities
These initiatives aim to improve access to healthcare for rare disease patients
Late-breaking data from DCR4Contrast study presented at EuroPCR 2023 and SCAI 2023 also shows an average reduction in the total number of angiograms obtained during each procedure of 26.3%
Concept Medical’s manufacturing arm has reduced its carbon footprint via in-house efficiency improvement programmes & green infrastructure
Single dose of Ferric Carboxymaltose (FCM) up to 750 mg of iron can be infused in 15 minutes
Farxiga is expected to have such a strong influence on the market due to the impressive results
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
Subscribe To Our Newsletter & Stay Updated
